Put CV Risks With Testosterone in Perspective

August 2023

New evidence will help clarify CV risk of testosterone replacement in men with hypogonadism.

Testosterone product labels caution about possible increased risk of heart attack and stroke. This stems from a 2015 FDA warning...based on small and observational trials with conflicting data.

Now a new study suggests transdermal 1.62% testosterone gel (AndroGel) daily for about 22 months does not increase risk of CV death, heart attack, or stroke more than placebo.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote